SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 240 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.33 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,657 | -11.8% | 1,438,422 | -3.9% | 0.07% | +4.6% |
| Q2 2023 | $44,979 | -10.9% | 1,496,322 | +7.4% | 0.06% | -3.0% |
| Q1 2023 | $50,487 | +12.3% | 1,393,522 | +10.6% | 0.07% | +8.1% |
| Q4 2022 | $44,963 | -99.9% | 1,260,522 | -1.5% | 0.06% | +1.6% |
| Q3 2022 | $43,336,000 | +7.3% | 1,280,222 | -8.4% | 0.06% | +27.1% |
| Q2 2022 | $40,402,000 | +0.5% | 1,397,022 | +12.3% | 0.05% | +2.1% |
| Q1 2022 | $40,191,000 | +11.2% | 1,243,522 | +0.4% | 0.05% | +4.4% |
| Q4 2021 | $36,133,000 | -2.4% | 1,239,122 | -10.8% | 0.04% | -6.2% |
| Q3 2021 | $37,035,000 | -20.7% | 1,388,622 | -8.4% | 0.05% | -17.2% |
| Q2 2021 | $46,684,000 | +1.3% | 1,516,222 | -13.9% | 0.06% | +1.8% |
| Q1 2021 | $46,083,000 | -1.0% | 1,760,222 | -4.8% | 0.06% | +11.8% |
| Q4 2020 | $46,534,000 | +19.5% | 1,849,522 | -1.0% | 0.05% | +30.8% |
| Q3 2020 | $38,940,000 | +2.9% | 1,868,500 | +17.3% | 0.04% | +18.2% |
| Q2 2020 | $37,829,000 | +133.1% | 1,592,800 | +76.5% | 0.03% | +106.2% |
| Q1 2020 | $16,231,000 | -25.7% | 902,200 | -2.1% | 0.02% | -5.9% |
| Q4 2019 | $21,848,000 | +41.4% | 921,100 | +63.8% | 0.02% | +30.8% |
| Q3 2019 | $15,449,000 | -22.7% | 562,200 | -7.0% | 0.01% | -27.8% |
| Q2 2019 | $19,993,000 | +23.4% | 604,200 | +30.7% | 0.02% | +20.0% |
| Q1 2019 | $16,199,000 | +42.0% | 462,300 | +34.6% | 0.02% | +25.0% |
| Q4 2018 | $11,411,000 | -51.6% | 343,500 | -26.6% | 0.01% | -50.0% |
| Q3 2018 | $23,559,000 | -64.8% | 467,900 | -60.6% | 0.02% | -33.3% |
| Q2 2018 | $66,858,000 | +380.7% | 1,188,390 | +291.3% | 0.04% | +140.0% |
| Q1 2018 | $13,909,000 | +1237.4% | 303,700 | +1063.6% | 0.02% | +1400.0% |
| Q4 2017 | $1,040,000 | -40.7% | 26,100 | -79.1% | 0.00% | -75.0% |
| Q3 2015 | $1,755,000 | -10.1% | 125,100 | +8.8% | 0.00% | 0.0% |
| Q2 2015 | $1,953,000 | +49.8% | 115,000 | -26.8% | 0.00% | +33.3% |
| Q4 2014 | $1,304,000 | +308.8% | 157,049 | +327.9% | 0.00% | +200.0% |
| Q3 2014 | $319,000 | – | 36,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |